In detail, Schinke et al. identified a prognostic MSC three-gene score, including collagen type IV alpha 1 (COL4A1), natriuretic peptide receptor 3 (NPR3), and integrin beta like 1 (ITGBL1), which is able to predict progression-free survival in MM patients and the progression of MGUS/SMM to MM [161]. This evidence concerns the gene NPR3 and Miyoshi myopathy.